Latest news with #postpartumDepression
Independent Singapore
6 days ago
- General
- Independent Singapore
'Sometimes old people must also be trained,' commenters tell man with overbearing mother-in-law
SINGAPORE: A young dad whose mother-in-law appears to want to take over a large part of his family's life took to Reddit to ask whether his mother-in-law (MIL) is overbearing or if she is actually justified. In a Jul 7 (Monday) post on r/askSingapore, u/GibunAnJoh-A wrote about h is difficulties with his MIL's actions and wrote that he wanted ' to see another perspective of unrelated people' before deciding on what to do. He and his wife, who are in their early 30s, became first-time parents to a little boy in March. Prior to their son's birth, his relationship with his MIL was cordial but started going south afterwards. He wrote that his MIL wants to carry the baby all the time and nags them to take her advice even when it runs counter to their parenting choices. She does not respect these choices but speaks against them. For example, when they told the grandparents they'd be preparing the baby for bedtime by 7 p.m., signalling that visits would end for the day by that time, the MIL interpreted it as limiting her time with the baby. The situation is particularly hard for the post author's wife, who is still struggling with postpartum depression. The couple is more inclined to follow the post author's mum, who has been a babysitter for 15 years. She will be the baby's primary caregiver when the post author's wife goes back to work. The post author and his wife's experience appears to be not uncommon, judging by the number of commenters on the post. A Reddit user who had the same experience wrote about having drawn firm boundaries with her own mother. 'The child is yours and your responsibility, so child-minding should not be subject to anyone else's beliefs. You know very well what is best, and please believe in that. Nobody, even your parents, should sway that. If in doubt, always check in with the doctor instead,' she wrote. Another commenter who agreed wrote, 'You really have to sit down and talk with your wife. As parents, what are your non-negotiables, and what to do if mom or MIL disregards the way you want to care for and educate your child? Set boundaries and be firm. Let parents or in-laws know right from the start that there are boundaries to be respected, and you will have an easier time later on.' 'This type of toxic parent can discard. Don't want to see/hear about her grandchild, right? Then your wife can just send updates to her dad in the future and just leave her mum entirely out of any updates or invitations to meet/play with/care for the baby. 'Don't need to play nice cuz your MIL will only be further encouraged in her toxic behaviour… Sometimes, old people must also be trained and disciplined in what is acceptable behaviour. New parents have (so much) to deal with and no time for other people's stupid drama. Luckily, you all still have your mum, who's a normal human being, to help care for the baby,' another observed. /TISG Read also: Man, 25, with $10K savings contemplates cutting ties with his toxic family, asks if he can make it alone
Yahoo
17-06-2025
- Business
- Yahoo
Sage, following Setbacks, to sell to Supernus for $561M
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sage Therapeutics, a brain drug developer that's dealt with a series of clinical setbacks, has agreed to be acquired by Supernus Pharmaceuticals in a deal worth $561 million. Supernus on Monday said it would pay $8.50 per share for Sage, an offer valuing shares at a roughly 27% premium to their previous closing price. The deal also includes a contingent value right worth up to $3.50 per share if certain sales and commercial milestones related Sage's lone product, the postpartum depression drug Zurzuvae, are met. Sage earlier this year turned down a $7.22-per-share offer from Zurzuvae development partner Biogen and sued the company, arguing it was being undervalued. The company has been evaluating 'strategic alternatives,' a process that included a search for a buyer, ever since. Sage has gone through a roller coaster ride since its founding more than a decade ago. Launched by Third Rock Ventures and run for many years by biotech veteran Jeff Jonas, the company aimed to develop brain drugs for a variety of conditions, from epilepsy and tremors to Huntington's disease. The company went public in 2014 to support that work and saw its share price swell to nearly $200 apiece a few years later as a pair of depression medicines advanced through testing. It brought to market not only the first medicine for postpartum depression, Zulresso, but the first pill for the condition, called Zurzuvae. It cut a multibillion-dollar partnership deal with Biogen, too. But Zulresso, a 60-hour infusion, never generated significant sales and Sage stopped marketing it at the end of the year. And the company had initially hoped to bring Zurzuvae to market for major depressive disorder — a much larger opportunity — but changed course and laid off staff after U.S. regulators asked for additional testing. Sage has suffered setbacks elsewhere, too, with experimental drugs failing studies in epilepsy, tremors, Alzheimer's, Huntington's and Parkinson's disease over the years. Company shares closed on Friday at $6.70 apiece and have fallen so low in recent months that Sage's board accused Biogen of lowballing the company with an earlier bid. The deal with Supernus feels 'like an unremarkable outcome for a company that was once one of the hottest stories' in brain drug research, wrote Stifel analyst Paul Matteis in a note to clients Monday. Matteis added that, for investors, though, the acquisition 'is a good end to the Sage story given the host of challenges facing the company.' In a separate note, RBC Capital Markets' Brian Abrahams called Supernus' offer 'fair' given the 'considerable time' it would have taken for Sage to become profitable. Abrahams also wrote that there is a 'very low likelihood' that Sage hits the majority of the sales targets that would bump up its sale price. Sage stockholders would get $1 per share if Zurzuvae hits $250 million in sales in the U.S. by 2027, and similar payouts if U.S. drug sales reach $300 million by 2028 and $375 million by 2030. Zurzuvae generated $72 million in U.S. sales in 2024. Biogen and Sage split U.S. profits. Recommended Reading Moderna inks another gene editing deal Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Health
- Yahoo
This one Oura Ring setting was a game changer for me after I had my baby
When you buy through links on our articles, Future and its syndication partners may earn a commission. I write about fitness tech for a living, but for the first four months of my son's life, I took everything off. I was struggling with postpartum depression, and devices telling me how little I'd moved, slept, or recovered was the last thing I needed. Women's Health Week This article is part of Tom's Guide's Women's Health Week — a series of content that explores how technology and the right workouts can support and empower women through every phase of life. Months later, when I finally felt strong enough to pop my Apple Watch and Oura Ring back on (an insignificant action to most, but a milestone to me), I leaned on a few features that really helped. I paused my rings on my Apple Watch, for example, removing the pressure to exercise on days when all I could do was sit on the sofa with my baby. I also used enabled Rest Mode on my Oura Ring — read on to find out what it does, why I did it and how to use it. According to Oura, Rest Mode allows you to 'focus on recovery when you feel tired, unwell, or need to slow down.' The Oura equivalent of pausing your Apple Watch rings, Rest Mode pauses your Activity Progress Goal, Activity Score and all activity-related contributors, allowing you to focus on rest. The Readiness and Sleep insights will also be adjusted to help you prioritize rest — something I wasn't getting with a newborn, but removing the pressure of not meeting activity goals helped. Oura says Rest Mode is designed for when you're feeling under the weather, when you're injured, sick, or traveling. If your Oura ring notices a spike in your average body temperature, you might get a notification that suggests switching to Rest Mode on your home screen. This is because the ring has noticed your body is under strain, and is suggesting that you should focus on recovery. If, like I did, you're turning on Rest Mode when you're not sick, here's the steps you'll need to follow: Go to the Menu in the top left corner of the Oura app home screen — the menu icon has three horizontal lines From here, scroll down and select the Rest Mode icon Then select Turn on Rest Mode Once you have enabled Rest Mode, the data you see on your home screen will be different. At the bottom of your home screen, you'll be able to see that Rest Mode is enabled. When you're feeling better, simply tap the notification banner at the bottom of the home screen, or go back to the Rest Mode setting on the sidebar and select 'Turn off and delete tags'. It's worth noting that once you turn Rest Mode off, your Activity Goal and Score will slowly return to normal, taking into account the time you've been resting. I had Rest Mode on for a couple of months as I mentally recovered, so it took my ring a week to ease me back into my normal goals. During this period, I was still able to view my step count, active calories, and calorie burn if I wanted to, but I found the mental break from hitting fitness targets was what I needed. Remember, these devices are designed to motivate you, not stress you out. If you're feeling overwhelmed, take them off, re-set, and remember that all movement is medicine, whether you're tracking it or not. How to set up menstrual tracking on your Apple Watch Which fitness trackers are the best for tracking women's health Samsung Galaxy Ring is changing the game for cycle tracking — here's how
Times
18-05-2025
- Entertainment
- Times
Die, My Love review — Jennifer Lawrence bombs in a maternal splatterfest
It's only taken eight years, but Jennifer Lawrence has finally delivered a companion piece for her outré mommy-horror Mother! And this one's terrible too, possibly even worse. At least Mother! demonstrated (pretentious) conceptual coherence, with Lawrence serving as a metaphor for the planet while her baby represented environmental destruction. In Die, My Love we're treated to a splatterfest that features Lawrence as a former writer called Grace who moves with her selfish, seedy, beer-swilling husband Jackson (Robert Pattinson) to a run-down woodland abode somewhere in middle America and has a baby that triggers an all-consuming psychotic breakdown. Fine on paper, and clearly the subject of postpartum depression can handle more big screen engagement than the few paltry mainstream titles that have attempted it
Washington Post
18-05-2025
- Entertainment
- Washington Post
Jennifer Lawrence stirs Oscar talk in Cannes for 'Die, My Love'
CANNES, France — Last year, the Cannes Film Festival produced three best actress nominees at the Oscars. This year's edition may have just supplied another. In Lynne Ramsay's 'Die, My Love,' Jennifer Lawrence and Robert Pattinson play a married couple with a newborn who move into an old country house. In Ramsay's messy and moving marital psychodrama, Lawrence plays an increasingly unhinged young mother named Grace whose postpartum depression reaches darkly hallucinatory extremes.
